Search results for "enzyme inhibitors"

showing 10 items of 559 documents

Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygena…

2002

Angiotensin II (Ang II) may be a key molecule in the development of atherosclerosis. Because the incidence of coronary atherosclerosis in premenopausal women is lower than that observed in men or postmenopausal women, we have investigated the effect of estrogens on Ang II–induced leukocyte recruitment in vivo using intravital microscopy in the rat mesenteric microcirculation. Superfusion for 60 minutes with Ang II induced a significant increase in leukocyte rolling flux, adhesion, and emigration. Administration of 17-β-estradiol (17-β-E) after 30 minutes of Ang II superfusion produced a reduction of these leukocyte responses by 55.1%, 72.7%, and 70.9%, respectively, an additional 30 minutes…

MaleSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyEndotheliumPhysiologyLeukocyte RollingProstacyclinCell CommunicationBiologyIn Vitro TechniquesLosartanReceptor Angiotensin Type 1Lymphatic SystemRats Sprague-DawleyAngiotensin Receptor AntagonistsCell MovementInternal medicinemedicineCell AdhesionLeukocytesAnimalsHumansSplanchnic CirculationEnzyme InhibitorsCells CulturedVenuleEstradiolAngiotensin IIEstrogen AntagonistsAntibodies MonoclonalEstrogensAngiotensin IIEpoprostenolRatsEndothelial stem cellNitric oxide synthasemedicine.anatomical_structureEndocrinologyProstaglandin-Endoperoxide Synthasesbiology.proteinEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsIntravital microscopymedicine.drugCirculation research
researchProduct

Diabetes-induced changes in endothelial mechanisms implicated in rabbit carotid arterial response to 5-hydroxytryptamine

2000

Abstract The influence of diabetes on endothelial mechanisms implicated in the response of isolated rabbit carotid arteries to 5-hydroxytryptamine (5- HT ) was studied. 5-HT induced a concentration–dependent contraction that was potentiated in arteries from diabetic rabbits with respect to that in arteries from control rabbits. Endothelium removal potentiated 5-HT contractions in arteries from both control and diabetic rabbits but increased the maximum effect only in arteries from diabetic rabbits. Incubation of arterial segments with N G -nitro- l -arginine ( l- NA) enhanced the contractile response to 5-HT. This l -NA enhancement was greater in arteries from diabetic rabbits than in arter…

MaleSerotoninmedicine.medical_specialtyContraction (grammar)ArginineEndotheliumIndomethacinIn Vitro TechniquesGuanidinesNitroarginineDiabetes Mellitus ExperimentalNitric oxidechemistry.chemical_compoundInternal medicineDiabetes mellitusmedicineAnimalsEnzyme InhibitorsPharmacologyLagomorphaDose-Response Relationship DrugbiologyVascular diseasebusiness.industryProstanoidmedicine.diseasebiology.organism_classificationCarotid Arteriesmedicine.anatomical_structureEndocrinologychemistryVasoconstrictionKetamineEndothelium VascularRabbitsNitric Oxide SynthasebusinessEuropean Journal of Pharmacology
researchProduct

The effects of nitric oxide on striatal serotoninergic transmission involve multiple targets: an in vivo microdialysis study in the awake rat

2004

Abstract The role of endogenous nitric oxide (NO) in N -methyl- d -aspartate (NMDA)-induced modulation of serotonin (5-HT) release in the striatum of freely moving rats has been studied using microdialysis technique. NMDA-induced increase in 5-HT release was significantly inhibited by selective nitric oxide synthase (nNOS) inhibitor S -methylthiocitrulline (S-Me-TC), ONOO − scavenger l -cysteine ( l -cys), and guanylate cyclase (GC) inhibitor 1 H [1,2,4]oxadiazolo[4,3- a ]quinoxalin-1-one (ODQ). These data suggest that modulation of 5-HT levels is linked to the formation of NO produced by NMDA receptor activation and that endogenously produced NO increases 5-HT concentrations both by stimul…

MaleSerotoninmedicine.medical_specialtyMicrodialysisN-MethylaspartateMicrodialysisNitric Oxide Synthase Type IPharmacologyNitric OxideSerotonergicSynaptic TransmissionNitric oxidechemistry.chemical_compoundSuperoxidesPeroxynitrous AcidInternal medicinemedicineAnimalsEnzyme InhibitorsRats WistarNeurotransmitterCyclic GMPMolecular Biologyneurotransmitters; modulators; transporters; and receptors; nitric oxide; serotonin; striatumbiologyGeneral NeuroscienceFree Radical ScavengersRatsNeostriatumNitric oxide synthasePeroxynitrous acidEndocrinologychemistryGuanylate Cyclasebiology.proteinNMDA receptorNeurology (clinical)SerotoninNitric Oxide SynthaseSignal TransductionDevelopmental Biology
researchProduct

Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabet…

2016

Introduction: Combination therapy is needed to control blood pressure (BP) in a large number of hypertensive patients with diabetes mellitus. Adherence to treatment is a major clinical problem; therefore, the time duration of the antihypertensive action of a drug determines BP control when a dose is skipped. Objectives: The aim was to determine whether the fixed-dose combination of olmesartan/amlodipine provides equal efficacy and safety as the perindopril/amlodipine combination when a drug dose is missed. Methods: In this noninferiority trial with a randomized, double-blind, double-dummy parallel group, controlled design, 260 patients received either olmesartan 20-40 mg/amlodipine 5-10 mg …

MaleSettore MED/09 - Medicina InternaAntihypertensive agentsPhysiologyMissed DoseTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood Pressure030204 cardiovascular system & hematologyPharmacologyEssential hypertensionlaw.invention0302 clinical medicineDiabetes mellitusRandomized controlled triallawAngiotensin II Type 1 Receptor BlockerDrug CombinationPerindoprilMedicine030212 general & internal medicineAntihypertensive agentTetrazoleImidazolesSettore MED/37 - NeuroradiologiaMiddle AgedCalcium Channel BlockersDrug CombinationsTreatment OutcomeHypertensionFemaleEssential HypertensionOlmesartanCalcium Channel BlockerCardiology and Cardiovascular MedicineType 2circulatory and respiratory physiologymedicine.drugHumanAdultmedicine.medical_specialtyAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineDiabetes mellitumissed dose; hypertension; therapeutic efficacyCombination therapyUrologytherapeutic efficacyNOMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal MedicineHumansOlmesartanAmlodipineamlodipine antihypertensive agents blood pressure diabetes mellitus olmesartan perindoprilImidazolemissed doseAgedbusiness.industryAngiotensin-Converting Enzyme Inhibitormedicine.diseaseAmlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus Type 2; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Perindopril; Tetrazoles; Treatment Outcome; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineBlood pressureDiabetes Mellitus Type 2PerindoprilAmlodipinebusinessAngiotensin II Type 1 Receptor Blockers
researchProduct

Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Ami…

2021

Inhibition of intracellular N-acylethanolamine-hydrolyzing acid amidase (NAAA) activity is a promising approach to manage the inflammatory response under disabling conditions. In fact, NAAA inhibition preserves endogenous palmitoylethanolamide (PEA) from degradation, thus increasing and prolonging its anti-inflammatory and analgesic efficacy at the inflamed site. In the present work, we report the identification of a potent, systemically available, novel class of NAAA inhibitors, featuring a pyrazole azabicyclo[3.2.1]octane structural core. After an initial screening campaign, a careful structure–activity relationship study led to the discovery of endo-ethoxymethyl-pyrazinyloxy-8-azabicyclo…

MaleStereochemistryAnti-Inflammatory AgentsPeptides and proteinsPyrazoleArticleAmidohydrolasesAmidaseRats Sprague-DawleyStructure-Activity Relationshipchemistry.chemical_compoundIn vivoN-AcylethanolamineDrug DiscoverymedicineAnimalsHumansSulfonesEnzyme InhibitorsIC50InhibitionInflammationchemistry.chemical_classificationPalmitoylethanolamideMolecular StructureInhibitorsSulfonamideMice Inbred C57BLMolecular Docking SimulationMechanism of actionchemistryMicrosomes LiverInhibitorsInhibitionSulfonesPeptides and proteinsInflammationPyrazolesMolecular Medicinemedicine.symptomProtein BindingTropanesJournal of Medicinal Chemistry
researchProduct

Nitric oxide- and cGMP-active compounds affect the discharge of substantia nigra pars reticulata neurons: in vivo evidences in the rat

2009

The nitric oxide (NO)-active drugs influence on the bioelectric activity of neurons of the pars reticulata of the substantia nigra was studied in urethane-anesthetized rats. A first group of animals was treated with 7-nitro-indazole (7-NI), a preferential inhibitor of neuronal NO synthase. In a second group of rats, electrophysiological recordings were coupled with microiontophoretic administration of Nomega-nitro-L-arginine methyl ester (L-NAME, a NO synthase inhibitor), 3-morpholino-sydnonimin-hydrocloride (SIN-1, a NO donor) and 8-Br-cGMP (a cell-permeable analogue of cGMP, the main second-messenger of NO neurotransmission). 7-NI and L-NAME caused a statistically significant decrease in …

MaleSubstantia nigra pars reticulataAction PotentialsDown-RegulationSubstantia nigraNitric Oxide Synthase Type INeurotransmissionPharmacologyBiologySettore BIO/09 - FisiologiaNitric oxidechemistry.chemical_compoundIn vivoAnimalsSingle unit electrophysiologyNitric Oxide DonorsEnzyme InhibitorsRats WistarCyclic GMPBiological PsychiatrySubstantia nigra pars reticulataNeuronsMicroiontophoresisNeural InhibitionNitric oxideIontophoresisRatsUp-RegulationSubstantia NigraPsychiatry and Mental healthElectrophysiologyNG-Nitroarginine Methyl EsterNeurologychemistryMolsidomineExcitatory postsynaptic potentialNeurology (clinical)Pars reticulataNeuroscienceSignal TransductionJournal of Neural Transmission
researchProduct

Role of calcineurin in Ca2+-induced release of catecholamines and neuropeptides

1998

Neurotransmission requires rapid docking, fusion, and recycling of neurotransmitter vesicles. Several of the proteins involved in this complex Ca2+-regulated mechanism have been identified as substrates for protein kinases and phosphatases, e.g., the synapsins, synaptotagmin, rabphilin3A, synaptobrevin, munc18, MARCKS, dynamin I, and B-50/GAP-43. So far most attention has focused on the role of kinases in the release processes, but recent evidence indicates that phosphatases may be as important. Therefore, we investigated the role of the Ca2+/calmodulin-dependent protein phosphatase calcineurin in exocytosis and subsequent vesicle recycling. Calcineurin-neutralizing antibodies, which blocke…

MaleSynaptobrevinCYCLOSPORINE-APhosphataseCalcineurin InhibitorsB-50 GAP-43Biologydynamin IBiochemistryBRAIN NERVE-TERMINALSExocytosisSynaptotagmin 1SincalidephosphataseGeneeskundeCellular and Molecular NeuroscienceNorepinephrineBacterial ProteinsPERMEATED SYNAPTOSOMESAnimalsratNEUROTRANSMITTER RELEASEMARCKSEnzyme InhibitorsRats WistarPROTEIN-KINASE-CDynaminCalcineurinTRANSMITTER RELEASEDYNAMIN-ISynapsinPhosphoric Monoester HydrolasesRatsINDUCED NORADRENALINE RELEASECalcineurinBiochemistryImmunoglobulin GStreptolysinsCalciumexocytosisCALMODULIN-BINDINGSynaptosomes
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Effects of nitric oxide-active drugs on the discharge of subthalamic neurons: microiontophoretic evidence in the rat.

2006

The presence of nitric oxide (NO) synthase and of soluble guanylyl cyclase, the main NO-activated metabolic pathway, has been demonstrated in many cells of the subthalamic nucleus. In this study, the effects induced on the firing of 96 subthalamic neurons by microiontophoretically administering drugs modifying NO neurotransmission were explored in anaesthetized rats. Recorded neurons were classified into regularly and irregularly discharging on the basis of their firing pattern. Nω-nitro-l-arginine methyl ester (L-NAME; a NO synthase inhibitor), 3-morpholino-sydnonimin-hydrocloride (SIN-1; a NO donor), S-nitroso-glutathione (SNOG; another NO donor) and 8-Br-cGMP (a cell-permeable analogue o…

MaleTime FactorsAction PotentialsNeurotransmissionInhibitory postsynaptic potentialNitric OxideSettore BIO/09 - FisiologiaNitric oxideS-Nitrosoglutathionechemistry.chemical_compoundSubthalamic NucleusAnimalsNitric Oxide DonorsEnzyme InhibitorsRats WistarCyclic GMPNeuronsAnalysis of VarianceIontophoresisDose-Response Relationship DrugChemistryGeneral Neuroscience8-Br-cGMP L-NAME SIN-1 SNOG subthalamic nucleusIontophoresisThionucleotidesRatsEnzyme ActivationSubthalamic nucleusNG-Nitroarginine Methyl EsterMolsidomineS-NitrosoglutathioneExcitatory postsynaptic potentialSoluble guanylyl cyclaseNeuroscience
researchProduct

A mouse model of in vivo chemical inhibition of retinal calcium-independent phospholipase A2 (iPLA2).

2013

International audience; Numerous studies have reported the implication of calcium-independent phospholipase A2 (iPLA2) in various biological mechanisms. Most of these works have used in vitro models and only a few have been carried out in vivo on iPLA2(-/-) mice. The functions of iPLA2 have been investigated in vivo in the heart, brain, pancreatic islets, and liver, but not in the retina despite its very high content in phospholipids. Phospholipids in the retina are known to be involved in several various key mechanisms such as visual transduction, inflammation or apoptosis. In order to investigate the implication of iPLA2 in these processes, this work was aimed to build an in vivo model of…

MaleTime Factors[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionDrug Evaluation PreclinicalInflammationBiochemistryRetinaGroup VI Phospholipases A2Mice03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhospholipase A2In vivomedicineAnimalsHomeostasisEnzyme Inhibitors030304 developmental biology0303 health sciencesRetinaDose-Response Relationship DrugbiologyPancreatic isletsRetinalGeneral MedicineCell biologyMice Inbred C57BLmedicine.anatomical_structureBiochemistrychemistryApoptosisModels Animalbiology.proteinmedicine.symptom[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryVisual phototransduction
researchProduct